Vericel (VCEL) Other Accumulated Expenses (2013 - 2026)
Vericel (VCEL) posted Other Accumulated Expenses of $116000.0 for Q2 2026, little changed sequentially from $116000.0 in Q1 2026, and down 1.69% YoY from $118000.0 in Q2 2025.
Analysis
Vericel (VCEL) Other Accumulated Expenses (2013 - 2026) Analysis & Trends
Vericel has reported Other Accumulated Expenses for 14 years, with the latest figure at $116000.0 in Q2 2026.
- Quarterly Other Accumulated Expenses fell 1.69% year-over-year to $116000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $116000.0 (down 1.69% YoY) and the FY2025 annual result came in at $116000.0, changed 0.0% from the prior year.
- Other Accumulated Expenses steadied at $116000.0 in Q2 2026 per VCEL's latest filing, from $116000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $118000.0 in Q2 2025 and troughed at $20000.0 in Q1 2023.
- A 5-year average of $78384.6 and a median of $116000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses changed 0.0% in 2022, then plunged 51.22% in 2023.
- Over 5 years, Other Accumulated Expenses stood at $41000.0 in 2022, then tumbled by 48.78% to $21000.0 in 2023, then soared by 452.38% to $116000.0 in 2024, then changed by 0.0% to $116000.0 in 2025, then changed by 0.0% to $116000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $116000.0, $116000.0, and $116000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 116,000.00 |
| Mar 31, 2026 | 116,000.00 |
| Dec 31, 2025 | 116,000.00 |
| Sep 30, 2025 | 116,000.00 |
| Jun 30, 2025 | 118,000.00 |
| Mar 31, 2025 | 116,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 20,000.00 |
| Dec 31, 2022 | 41,000.00 |
| Sep 30, 2022 | 41,000.00 |
| Jun 30, 2022 | 41,000.00 |
| Mar 31, 2022 | 41,000.00 |
| Dec 31, 2021 | 41,000.00 |
| Sep 30, 2021 | 41,000.00 |
| Jun 30, 2021 | 41,000.00 |
| Mar 31, 2021 | 41,000.00 |
| Dec 31, 2020 | 41,000.00 |
| Sep 30, 2020 | 41,000.00 |
| Jun 30, 2020 | 41,000.00 |